Our mission is to leverage our unique platform technology and expertise to discover and develop novel small molecule therapies aimed at addressing serious unmet medical needs for patients suffering from autoimmune and inflammatory diseases. EydisBio is the first group to develop a highly selective, orally bioavailable TAK1 inhibitor for the treatment of autoimmune and inflammatory diseases. Utilizing our highly innovative chemistry platform, we pride ourselves on our ability to develop highly selective kinase inhibitors towards various diseases.
